

## BOARD SUBCOMMITTEE ASSURANCE REPORT

Presented for: **Information**

Committee Name; Audit Committee

Presented by : Mike Ellwood, NED (Audit Committee Chair)

Date of Committee Meeting 1/04/2021.

Points of  
Escalation

*None.*

Key Issues

Summary of main points discussed.  
Losses and Special payments reviewed.

Draft Risk Management Policy discussed and recommended for Board approval.

Annual Report and accounts 2020/21 timetable and process discussed and agreed.

Internal Audit progress Report reviewed against plan and follow up actions.

Fraud, Bribery and Corruption. Local counter fraud report scrutinized.

Gifts and Hospitality policy paper reviewed and debated.



## Risks

**Risk Report to review the Trust's high and significant risks was discussed.**

**High Risks number 20 in total and all have actions in date. Level of control in 5 described as inadequate.**

**Significant Risks number 28 in total with 3 out of date and 3 with levels of control described as inadequate.**

**All risks described as uncontrolled or inadequate are subject to close scrutiny and review.**

**Risk training now re-established with bespoke training now offered on a priority basis.**

**Spotlight  
Outstanding  
Practice and  
Innovation**

We received a report on an initiative between Corporate Governance Compliance team and the Local Counter Fraud service on Declarations of interest and triangulation of such through the Association of British Pharmaceutical Industry.

<b>Author:</b>	Mike Ellwood
<b>Job Title</b>	NED Audit Chair.
<b>Date:</b>	May 2021.